The added value of metabolic imaging with FDG-PET in oesophageal cancer: Prognostic role and prediction of response to treatment

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 7, 2006, Pages 753-758

  Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHINA; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EDITORIAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EUROPE; FRANCE; HUMAN; IMAGING; INDIA; IRAN; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; SOUTH AFRICA; SWITZERLAND; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33745530607     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0147-x     Document Type: Editorial

References (38)

1. Wu X, Chen VW, Ruiz B, Andrews P, Su LJ, Correa P. Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences. Cancer 2006;106:683-92
2. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc 2005;97:1471-8
3. Kelsen DP. Multimodality therapy of local regional esophageal cancer. Semin Oncol 2005;32:S6-10
4. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004;60:427-36
5. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Developing an appropriate staging system for esophageal carcinoma. J Am Coll Surg 2005;201:884-90
6. Nishimaki T, Tanaka O, Ando N, Ide H, Watanabe H, Shinoda M, et al. Evaluation of the accuracy of preoperative staging in thoracic esophageal cancer. Ann Thorac Surg 1999;68:2059
7. Bergman JJ, Fockens P. Endoscopic ultrasonography in patients with gastro-esophageal cancer. Eur J Ultrasound 1999;10:127
8. Catalane MF, Alcocer E, Chak A, Nguyen CC, Raijaman I, Geenen JE, et al. Evaluation of metastatic celiac axis lymph nodes in patients with esophageal carcinoma: accuracy of EUS. Gastrointest Endosc 1999;50:352
9. Kuipers EJ, Haringsma J. Diagnostic and therapeutic endoscopy. J Surg Oncol 2005;92:209-30
10. Castillo E, Lawler LP. Diagnostic radiology and nuclear medicine. J Surg Oncol 2005;92:191-202
11. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of esophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521
12. Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133
13. Flamen P, Lerut T, Haustermans K, Van Cutsem E, Mortelmans L. Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer. Q J Nucl Med Mol Imaging 2004;48:96-108
14. Korst RJ, Altorki NK. Imaging for esophageal tumors. Thorac Surg Clin 2004;14:61-9
15. Imdahl A, Hentschel M, Kleimaier M, Hopt UT, Brink I. Impact of FDG-PET for staging of oesophageal cancer. Langenbeck's Arch Surg 2004;389:283-8
16. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005;103:148-56
17. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in esophageal cancer. Incremental value over computed tomography. Clin Positron Imaging 1999;2:255-60
18. Luketich JD, Schauer P, Urso K, Kassis E, Ferson P, Keenan R, et al. Future directions in oesophageal cancer. Chest 1998;113:120-2
19. 18F-FDG accumulation in the distal oesophagus. Eur J Nucl Med Mol Imaging 2005;32:990-2
20. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006;79:32-6
21. Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, et al. The additional value of PET/CT over PET in FDG imaging of esophageal cancer. Eur J Nucl Med Mol Imaging 2005;32:918-24
22. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005;7:422-30
23. Flamen P, Lerut A, van Cutsem E, De Wever W, Peelers M, Stroobans S, et al. Utility of PET for the staging of patients with potentially operable oesophageal carcinoma. J Clin Oncol 2000;18:3202-10
24. Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, et al. Whole body FDG PET for staging oesophageal cancer comparison with computed tomography. Clin Nucl Med 2000;25:882-7
25. Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systematic review. Radiology 2005;236:841-5
26. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FDG-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 2004;73:269-75
27. Leong T, Everitt C, Yuen K, Condron S, Hui A, Ngan SY, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 2006;78:254-61
28. van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 2006 Mar 22 [Epub ahead of print]
29. Duong CP, Demitriou H, Weih L, Thompson A, Williams D, Thomas RJ, et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of esophageal cancer. Eur J Nucl Med Mol Imaging 2006 DOI 10.1007/s00259-005-0028-8
30. Blackstock AW, Farmer MR, Lovato J, Mishra G, Melin SA, Oaks T, et al. A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2006;64:455-60
31. Duong CP, Hicks RJ, Weih L, Drummond E, Leong T, Micheal M, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in esophageal cancer. Eur J Nucl Med Mol Imaging 2006 DOI 10.1007/s00259-005-0040-z
32. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of oesophageal cancer using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998;39:1002-7
33. Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, et al. Preoperative 18-F-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006;81:1076-81
34. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of oesophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9
35. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of oesophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65
36. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8
37. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-85
38. 18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472-8